New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences' Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach

Core Insights - STRATA Skin Sciences, Inc. has highlighted a recent study demonstrating the efficacy of its 308nm Excimer laser combined with a JAK inhibitor for treating localized non-segmental vitiligo, showing superior results compared to monotherapy [1][2][4] Study Findings - The study involved 251 patients and revealed five key findings: 1. Mechanistic synergy between JAK inhibitors and Excimer laser therapy [7] 2. A 14.20% higher repigmentation rate with the combination therapy [7] 3. A 100% significant efficacy rate after 52 weeks of treatment [7] 4. At one-year follow-up, the combination group showed 96.5% pigmentation stability and an 8.8% relapse rate [7] 5. The treatment exhibited an excellent safety profile with no serious adverse events [7] Clinical Validation - The study adds to over 400 existing studies validating the 308nm Excimer laser as a cornerstone therapy for various inflammatory and autoimmune skin diseases [3][4] - The combination therapy is positioned as a personalized medicine approach, allowing for tailored treatment based on laser exposure duration and dosage [3] Company Strategy - The company is pursuing expanded reimbursement for its treatments, leveraging the strong clinical evidence from the recent study [3][4] - STRATA continues to work with regulators to enhance access to its treatment modalities by early 2026 [3]